U.S. markets close in 2 hours 28 minutes
  • S&P 500

    4,073.35
    +65.34 (+1.63%)
     
  • Dow 30

    32,568.40
    +344.98 (+1.07%)
     
  • Nasdaq

    11,918.04
    +255.25 (+2.19%)
     
  • Russell 2000

    1,834.20
    +50.77 (+2.85%)
     
  • Crude Oil

    113.82
    -0.38 (-0.33%)
     
  • Gold

    1,819.70
    +5.70 (+0.31%)
     
  • Silver

    21.75
    +0.20 (+0.92%)
     
  • EUR/USD

    1.0550
    +0.0111 (+1.07%)
     
  • 10-Yr Bond

    2.9620
    +0.0850 (+2.95%)
     
  • GBP/USD

    1.2476
    +0.0153 (+1.24%)
     
  • USD/JPY

    129.3440
    +0.2910 (+0.23%)
     
  • BTC-USD

    30,158.67
    +549.39 (+1.86%)
     
  • CMC Crypto 200

    677.98
    +435.30 (+179.37%)
     
  • FTSE 100

    7,518.35
    +53.55 (+0.72%)
     
  • Nikkei 225

    26,659.75
    +112.70 (+0.42%)
     

Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RANCHO CORDOVA, Calif., Sept. 7, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference.

If you are an institutional investor and would like to listen to the company's on-demand presentation, please click on the following link to register for the conference: www.hcwevents.com. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the company.

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.

Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-participate-in-the-hc-wainwright-23rd-annual-global-investment-conference-301369008.html

SOURCE ThermoGenesis Holdings, Inc.